Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Doxorubicin in Advanced Soft Tissue Sarcomas
NCT03009201Phase 1Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Mar 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in soft tissue sarcoma (STS), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Incidence of dose limiting toxicities at 21 days. Started Mar 2017; status: completed.
02
Drugs
ribociclib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03009201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009201.